
    
      This is an open label, monocenter, explorative study . A total of 9 patients will be included
      in the study in three sequential cohort of 3 patients each. Patients will enter into the
      study after meeting the inclusion and exclusion criteria and signing the Informed Consent
      Form.

      The first three patients will be treated for 16 weeks starting 40 days after transplantation;
      if all three patients will complete the treatment period without any serious treatment
      related adverse event then the recruitment of second cohort of patients will be opened and
      patients treated starting from 20 days after transplantation. The same procedure will be
      applied for the third cohort of patients starting treatment from day of transplantation.
    
  